New combo therapy aims to tackle tough prostate cancer

NCT ID NCT07172685

Recruiting now Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a combination of hormone therapy, chemotherapy, and targeted ultrasound for men with metastatic prostate cancer that has spread widely. The goal is to see if adding focused ultrasound to standard triple therapy can better control the disease. About 116 men will take part in this single-arm trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Darolutamide, Docetaxel, ADT (hormone therapy), and High-Intensity Focused Ultrasound (HIFU)
What this could lead to: If successful, this combination could improve control of metastatic prostate cancer and delay disease progression.
What could go wrong: This is an early exploratory study with only 116 participants, so results may not apply to all patients. The added HIFU procedure carries risks like infection or urinary issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER WITH HIGH TUMOR BURDEN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Qilu hospital
RECRUITING

Jinan, Shandong, 276600, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.